Surrozen develops antibody-based therapies that target the Wnt pathway, with a focus on eye diseases. It last closed at $29.98 on Nov 17, down 7.24% on the day. The average 12-month price target from 3 analysts is $65.33 (+117.9% from the last close), with a high of $80.00 and a low of $54.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Each firm's latest rating on SRZN in the past 90 days
Average 12-month target
$65.33
▲ 117.9% upside
Based on 3 analysts who set a price target on SRZN in the past 90 days. The average target is $65.33, with a high of $80.00 and a low of $54.00, compared with the last close of $29.98.
Low $54.00Avg $65.33High $80.00
Blue marker: last close $29.98
Highest target$80.00
Average target$65.33
Lowest target$54.00
Latest rating changes
GuggenheimMaintained
Nov 12Buy$80
Cantor FitzgeraldMaintained
Nov 10Buy$62
HC Wainwright & Co.Target raised
Sep 25Buy$44 → $54
HC Wainwright & Co.Reiterated
Aug 10Buy$44
Date
Firm
Action
Rating
Price target
Nov 12
Guggenheim
Maintained
Buy
$80
Nov 10
Cantor Fitzgerald
Maintained
Buy
$62
Sep 25
HC Wainwright & Co.
Target raised
Buy
$44 → $54
Aug 10
HC Wainwright & Co.
Reiterated
Buy
$44
Loading…
Technical Analysis
SRZN · as of the Nov 17 close · updated after every close
Uptrend
The stock is 1% above its 20 day and 12% above its 50 day average. It is 14% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 53). The nearest support is the 20 day average at $29.75, and the nearest resistance the Pivot at $30.39.
Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 7.8%/day
Key levels
$37.8352 week high+26.2%
$31.47Pivot R1+5.0%
$30.97Swing high (Oct 9)+3.3%
$30.39Pivot+1.4%
$29.98Last close
$29.7520 day average−0.8%
$28.89Pivot S1−3.6%
$26.2850 day average−12.3%
$25.73200 day average−14.2%
$25.00Swing low (May 20)−16.6%
$24.55100 day average−18.1%
$12.5252 week low−58.2%
Indicators
RSI (14)
52.61
Middle of its range
Neutral
MACD
1.50
Below its signal line
Bearish
Stochastic
60.4
Middle of its range
Neutral
ADX (14)
33.0
Trending up
Williams %R
-62.4
Oversold below −80, overbought above −20
Neutral
CCI (20)
24.1
Oversold below −100, overbought above 100
Neutral
Rate of change
−0.5%
Change over 10 sessions
Bearish
ATR (14)
$2.35
Typical daily range, 7.8% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Uptrend
Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityNormal, 17.0%/day
Key levels
$37.8352 week high+26.2%
$31.47Pivot R1+5.0%
$30.97Swing high (Oct 9)+3.3%
$30.39Pivot+1.4%
$29.98Last close
$29.7520 day average−0.8%
$28.89Pivot S1−3.6%
$26.2850 day average−12.3%
$25.73200 day average−14.2%
$25.00Swing low (May 20)−16.6%
$24.55100 day average−18.1%
$12.5252 week low−58.2%
Indicators
RSI (14)
56.67
Middle of its range
Neutral
MACD
1.66
Above its signal line
Bullish
Stochastic
67.9
Middle of its range
Neutral
ADX (14)
20.0
Weak trend
Williams %R
-36.2
Oversold below −80, overbought above −20
Neutral
CCI (20)
115.4
Oversold below −100, overbought above 100
Overbought
Rate of change
+57.8%
Change over 10 sessions
Bullish
ATR (14)
$5.09
Typical daily range, 17.0% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for SRZN
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how SRZN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow SRZN usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How SRZN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SRZN is in one of them and how their past SRZN trades turned out.
Surrozen is a biotechnology company based in South San Francisco, California. It develops antibody-based drug candidates that act on the Wnt pathway, a signaling system involved in tissue repair. Its main focus is eye disease, with candidates in development for diabetic macular edema and the wet form of macular degeneration, conditions treated by eye specialists. The company also has a development agreement with Boehringer Ingelheim for a related candidate.